Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug

Summit Therapeutics’ SMMT shares fell about 17% to near $11.70 after the FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer, citing insufficient overall survival proof. Jefferies sees limited downside; Barclays cut its target to $18.

Original reporting
Published Nov 16, 2026, 4:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug — source image
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

The regulatory denial directly caused a 17% pre‑market decline, pushing the stock to a 52‑week low and prompting analysts to cut price targets.

02

Market read

The FDA denial is a primary catalyst for Summit's stock, creating immediate trading opportunity and broader biotech sector implications.

03

What to watch

Potential partnership with Akeso and upcoming HARMONi‑3 data could mitigate the impact if results are compelling.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Summit Therapeutics announced an FDA Complete Response Letter for its ivonescimab trial in EGFR‑mutated NSCLC, citing insufficient overall‑survival benefit.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

FDA issued a Complete Response Letter rejecting ivonescimab, sending Summit Therapeutics shares down ~17% to a new 52‑week low.

Expected impact

likely further downside as investors price in the regulatory setback

Evidence & confidence

Regulatory denial is a material catalyst for biotech stocks; the stock already fell 17% pre‑market and may continue to sell off on the news.

Market effects

Biotech sector may see heightened scrutiny on lung‑cancer programs, pressuring peers with similar trials.

U.S. biotech stocks could face short‑term pressure; limited impact outside North America.

Regulatory outcomes in the U.S. often set precedent for global approvals, modestly affecting global biotech sentiment.

Counterpoint

If Summit can generate additional data to meet the OS endpoint, the stock may rebound on a future resubmission.

Key entities

  • Summit Therapeutics Inc.

    Biopharma developing ivonescimab for lung cancer.

  • FDA

    U.S. Food and Drug Administration issuing the rejection.

  • Akeso

    Collaborator on Summit's Phase III studies.

Related articles

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.

$SMMTHighAI 9/10

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Summit Therapeutics (SMMT) shares fell 20% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient evidence of effectiveness. The drug showed progression-free survival benefits but failed to meet overall survival endpoints. The setback delays U.S. launch plans and creates regulatory uncertainty. Year-to-date, SMMT shares are down 19.1%.

$SMMTHighAI 8/10

SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter

Summit Therapeutics (SMMT) saw price target reductions from Barclays ($18) and Citi ($42) after the FDA issued a complete response letter for its lung cancer treatment, ivonescimab. Barclays noted potential implications for the lung cancer program, while Citi cited the CRL as the reason for its reduction. Jefferies maintained a 'Buy' rating with a $30 target, stating the setback was anticipated. SMMT shares fell 11% following the news.

$SMMTHighAI 8/10

Summit Therapeutics tumbles 13% after FDA rejects lung cancer drug application

Summit Therapeutics (SMMT) shares dropped 13% after the FDA rejected its lung cancer drug application, citing insufficient overall survival benefit. The HARMONi trial showed improved progression-free survival but missed the statistical significance threshold for overall survival. Jefferies noted the decision was anticipated and maintained focus on the upcoming HARMONi-3 trial results.